---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-25-097564"
form_type: "8-K"
ticker: "BJDX"
cik: "0001704287"
company_name: "Bluejay Diagnostics, Inc."
filed_at: "2025-10-09T23:59:59+00:00"
generated_at: "2026-05-17T04:12:06.200244+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "medium"
source: SEC EDGAR
---

# Bluejay expands SanyoSeiko partnership for Symphony platform commercialization

## Summary
- SanyoSeiko will serve as contract manufacturing organization for analyzers, cartridges, and components.
- SanyoSeiko to oversee fulfillment, kit assembly, labeling, packaging, shipping, and quality control.
- Partnership includes manufacturing redevelopment, raw material sourcing, vendor compliance, and regulatory support.
- Bluejay's Symphony platform is a near-patient testing system for biomarkers like IL-6 in sepsis management.
- No financial terms disclosed; Symphony not yet FDA cleared.

## SEC filing metadata
- accession: 0001213900-25-097564
- form_type: 8-K
- ticker: BJDX
- cik: 0001704287
- company_name: Bluejay Diagnostics, Inc.
- filed_at: 2025-10-09T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: medium
- sec_items: 1.01, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1704287/000121390025097564/0001213900-25-097564-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1704287/000121390025097564/ea0260646-8k_bluejay.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-25-097564
- JSON: https://secwatch.observer/filing/0001213900-25-097564.json
- Plain text: https://secwatch.observer/filing/0001213900-25-097564.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.